Exploiting the uniqueness of the soloMER technology for the development of next-generation, super-potent drug modalities for chronic autoimmune inflammation diseases, and bevond
28 April 2022
Programme lead in autoimmune inflammation diseases drug discovery at Elasmogen Limited, a University of Aberdeen spinout biotech company. His research interest broadly encompasses biologics drug discovery and drug development for chronic diseases such as autoimmune inflammation diseases and
cancers. He holds a Bharm (University of Benin, Nigeria) MsC with distinction and PhD funded by Scottish Universities Life Sciences Alliance (SULSA) / Merck Sharp & Dohme (MSD) (all University of Aberdeen, Scotland) and PGCert in IP Law from the University of South Africa (UNISA, 2018). He is also a Fellow of the UK Higher Education Academy and holds a lectureship position in the School of Medicine and Medical Sciences at the University of Aberdeen. Obinna is the president of a Scottish registered foundation (FISE) focused on bridging the life sciences knowledge gap between the UK and Africa.
In October 2021, he was awarded the prestigious UKRI Future Leaders Fellowship with a £2M grant to continue advancing his cutting-edge drug discovery research and leadership development.